Iterum Therapeutics PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Iterum Therapeutics reports its 2024 financial results and continues to explore strategic alternatives for its approved drug, ORLYNVAH, while addressing going concern uncertainties.
Iterum Therapeutics' 10-K filing details its share capital, regulatory environment, and strategic focus on its sulopenem program.